The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM

PHASE3CompletedINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

October 26, 2015

Primary Completion Date

June 15, 2017

Study Completion Date

June 15, 2017

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

Dapagliflozin 5 mg

Dapagliflozin, a blood glucose lowering drug. Oral dose

DRUG

Dapagliflozin 10mg

Dapagliflozin, a blood glucose lowering drug. Oral dose

Trial Locations (24)

Unknown

Research Site, Aizu Wakamatsu-shi

Research Site, Chūōku

Research Site, Fukuoka

Research Site, Fukuyama-shi

Research Site, Funabashi-shi

Research Site, Hamamatsu

Research Site, Hirosaki-shi

Research Site, Ise-shi

Research Site, Kagoshima

Research Site, Koriyama-shi

Research Site, Kumamoto

Research Site, Kunitachi-shi

Research Site, Minatoku

Research Site, Nagoya

Research Site, Oyama-shi

Research Site, Ōita

Research Site, Ōtsu

Research Site, Sapporo

Research Site, Sendai

Research Site, Shinjyuku-ku

Research Site, Suita-shi

Research Site, Tama-shi

Research Site, Tsukuba

Research Site, Yokohama

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY